VYNE Therapeutics and Yarrow Bioscience Agree to Merge, Creating Thyroid-Focused Biotech
VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. have entered into a definitive all-stock merger agreement to combine their operations and form a new company focused on developing treatments for autoimmune thyroid diseases. Following completion of the transaction, the combined company is expected to operate as Yarrow Bioscience, Inc. and remain listed on Nasdaq.
The merger brings together VYNE’s public-company infrastructure and development experience with Yarrow’s clinical-stage pipeline, centered on a targeted biologic approach to thyroid disorders.
Lead Program Targets Graves’ Disease and Thyroid Eye Disease
After the merger, the company plans to focus primarily on YB-101, a monoclonal antibody designed to block the thyroid-stimulating hormone receptor (TSHR). This mechanism aims to address the underlying drivers of Graves’ disease and thyroid eye disease, conditions that currently have limited disease-modifying treatment options.
The company expects to initiate a Phase 1b/2b clinical trial of YB-101 in Graves’ disease in the first half of 2026, with early clinical data anticipated in 2027. A separate Phase 1 study in thyroid eye disease is already underway in China through a licensing partner.
Financing Supports Multi-Year Development Plan
The merger is supported by approximately $200 million in committed financing from a group of established life sciences investors. The combined company expects this capital to fund operations into 2028, providing runway to advance YB-101 through key clinical milestones.
Prior to closing, VYNE plans to distribute a pre-closing cash dividend to its shareholders, representing excess net cash not required for the combined company’s operating plan.
Leadership and Closing Timeline
Following the merger, Rebecca Frey, Pharm.D., President and CEO of Yarrow Bioscience, is expected to lead the combined organization. The transaction has been unanimously approved by the boards of both companies and is targeted to close in the second quarter of 2026, subject to customary shareholder and regulatory approvals.
Sector Context
The transaction reflects continued consolidation within specialty biotech as companies seek to combine capital, pipelines, and operational capabilities around focused therapeutic areas. Autoimmune thyroid diseases represent a growing area of interest as developers pursue more targeted biologic approaches aimed at underlying disease mechanisms rather than symptom management.
